Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell Holdings PLC teams up with Sweden's leading research organisation

Discussions with the rheumatology unit at Karolinska Institutet will explore the role of citrullinated proteins in the treatment of cancer.
Scancell Holdings PLC teams up with Sweden's leading research organisation
The scientists are looking to share information.

Drug developer Scancell Holdings PLC (LON:SCLP) is teaming up with Sweden’s leading research organisation -  a collaboration that may aid the development of one of its two breakthrough technologies.

Discussions with the rheumatology unit at Karolinska Institutet will explore the role of citrullinated proteins in the treatment of cancer.

These particular proteins are more commonly associated with arthritis, though Scancell’s work suggests they are key to tumour growth.

This avenue of research led the company to develop the Moditope platform technology that overcomes the immune suppression induced by tumours themselves.

The work of professors Lars Klareskog and Vivianne Malmström, of the Karolinska Institutet, has focused on rheumatoid arthritis.

“We believe that this strategic collaboration with Karolinska will enhance our joint understanding of the role that citrullination plays in both cancer and rheumatoid arthritis, and will help us develop the Moditope platform to its full potential," said professor Lindy Durrant, joint chief executive of Scancell who is also Professor of Cancer Immunotherapy at Nottingham University.

Ian_55ae0ddd437b7.jpg
Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile

Scancell Holdings Plc Timeline

Article
August 22 2016

Related Articles

antibiotic.jpg
March 02 2016
In all 1,200 patients will take part in the global trials run by Motif’s partner Covance.
stem-cells.jpg
February 25 2016
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.
inhaler.jpg
April 05 2016
If the market worked as perfectly as its more rabid advocates insist, we wouldn’t have attractive anomalies such as Synairgen..

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.